arrow
A

Alexis B. Cortot

institut national de la santé et de la recherche médicale (inserm)
H指数:44
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact

帕博利珠单抗与帕博利珠单抗联合化疗在PDL1 ⩾50%的晚期非小细胞肺癌患者中的比较,根据肿瘤侵袭性和临床影响

2025-11-300
OA
Efficacy of neratinib-based therapy in ERBB2-mutant lung adenocarcinomas: findings from 2 international phase 2 studies

奈拉替尼为基础疗法在ERBB2突变型肺腺癌中的疗效:2项国际II期研究的结果

2025-10-010
PRE
Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study

法国早期准入项目中阿曼曲单抗在EGFR外显子20突变非小细胞肺癌中的真实世界有效性与安全性:Amexon 20 GFPC研究

2025-09-260
PRE
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory EGFR-mutated Non-small Cell Lung Cancer: Patient Satisfaction and Resource Utilization Results from the PALOMA-3 Study

皮下给药与静脉给药的Amivantamab(联合Lazertinib)在EGFR突变型非小细胞肺癌难治患者中的应用:PALOMA-3研究中的患者满意度与资源利用结果

2025-07-100
OA
Explore-ALK (GFPC 03-2019): A real-world prospective, multicenter study of advanced ALK rearranged non-small cell lung cancer patients

探索-ALK (GFPC 03-2019):一项真实世界前瞻性、多中心研究,探讨ALK重排的非小细胞肺癌患者

2024-09-010
PRE
Environmental pollutants and molecular alterations in non-small cell lung cancer: Insights from the KBP-2020 cohort study

环境污染物与非小细胞肺癌中的分子改变:KBP-2020队列研究的见解

2024-09-010
PRE
Survival and Prognostic Factors After Adrenalectomy for Secondary Malignancy

肾上腺继发性恶性肿瘤切除术后的生存和预后因素

2024-08-070
PRE
Daily Caffeine Consumption May Increase the Risk of Acute Kidney Injury Related to Platinum-Salt Chemotherapy in Thoracic Cancer Patients: A Translational Study

每日摄入咖啡因可能会增加胸部癌症患者与铂盐化疗相关的急性肾损伤的风险: 一项转化研究

2024-03-190
OAAI
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Amivantamab联合化疗联合或不联合lazertinib治疗奥希替尼治疗EGFR突变晚期NSCLC后疾病进展: III期MARIPOSA-2研究的主要结果

2024-01-01101
OA